On November 9, BEONE MEDICINES rose 3.28% in regular trading, with the stock trading at HK$252.0 and turnover of HK$188 million.
The clearest catalyst in recent disclosures was earnings-driven: the company reported third-quarter revenue of $1.89 billion, ahead of market estimates of $1.758 billion, adjusted EPS of $4.59 versus a $1.97 estimate, and lifted full-year revenue guidance to $6.9 billion-$7.0 billion while raising GAAP operating profit guidance to $1.2 billion-$1.3 billion.
Additional details showed third-quarter global revenue increased 34% year over year, product revenue rose 33%, and Brukinsa revenue reached about $1.4 billion, up 34%. In its domestic disclosure, the company also said it expects full-year revenue of RMB 46.3 billion-RMB 47.0 billion and operating surplus after costs of RMB 8.4 billion-RMB 9.0 billion, marking its third guidance increase this year. That combination of a clear beat and stronger outlook helps explain the renewed buying interest.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments